These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 27717544)

  • 1. Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
    Jadhavar PS; Ramachandran SA; Riquelme E; Gupta A; Quinn KP; Shivakumar D; Ray S; Zende D; Nayak AK; Miglani SK; Sathe BD; Raja M; Farias O; Alfaro I; Belmar S; Guerrero J; Bernales S; Chakravarty S; Hung DT; Lindquist JN; Rai R
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5222-5228. PubMed ID: 27717544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
    Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
    Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
    Ai J; Wang Y; Dar JA; Liu J; Liu L; Nelson JB; Wang Z
    Mol Endocrinol; 2009 Dec; 23(12):1963-72. PubMed ID: 19855091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer.
    Seidel C; Schnekenburger M; Mazumder A; Teiten MH; Kirsch G; Dicato M; Diederich M
    Biochem Pharmacol; 2016 Jan; 99():31-52. PubMed ID: 26549368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
    Gibbs A; Schwartzman J; Deng V; Alumkal J
    Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16663-8. PubMed ID: 19805354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.
    Gryder BE; Akbashev MJ; Rood MK; Raftery ED; Meyers WM; Dillard P; Khan S; Oyelere AK
    ACS Chem Biol; 2013 Nov; 8(11):2550-60. PubMed ID: 24004176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.
    Basak S; Pookot D; Noonan EJ; Dahiya R
    Mol Cancer Ther; 2008 Oct; 7(10):3195-202. PubMed ID: 18852123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugging the HDAC6-HSP90 interplay in malignant cells.
    Krämer OH; Mahboobi S; Sellmer A
    Trends Pharmacol Sci; 2014 Oct; 35(10):501-9. PubMed ID: 25234862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
    Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment.
    Zhou M; Zheng H; Li Y; Huang H; Min X; Dai S; Zhou W; Chen Z; Xu G; Chen Y
    Aging (Albany NY); 2021 Feb; 13(5):6982-6998. PubMed ID: 33621955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the androgen receptor pathway in prostate cancer.
    Chen Y; Sawyers CL; Scher HI
    Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.
    Sato S; Katsushima K; Shinjo K; Hatanaka A; Ohka F; Suzuki S; Naiki-Ito A; Soga N; Takahashi S; Kondo Y
    Cancer Res; 2016 Jul; 76(14):4192-204. PubMed ID: 27216188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis.
    Ryu HW; Shin DH; Lee DH; Choi J; Han G; Lee KY; Kwon SH
    Cancer Lett; 2017 Apr; 391():162-171. PubMed ID: 28153791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
    Zwick V; Simões-Pires CA; Nurisso A; Petit C; Dos Santos Passos C; Randazzo GM; Martinet N; Bertrand P; Cuendet M
    Bioorg Med Chem Lett; 2016 Oct; 26(20):4955-4959. PubMed ID: 27650925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
    Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
    Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.